Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Jelinek, T. (T.) | - |
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | Hajek, R. (R.) | - |
dc.date.accessioned | 2023-03-09T08:36:07Z | - |
dc.date.available | 2023-03-09T08:36:07Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Jelinek, T. (T.); Paiva, B. (Bruno); Hajek, R. (R.). "Update on PD-1/PD-L1 inhibitors in multiple myeloma". Frontiers in immunology. 9, 2018, 2431 | es |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://hdl.handle.net/10171/65653 | - |
dc.description.abstract | The treatment of cancer, especially of various types of solid tumors, has been revolutionized by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success amongst hematologic malignancies, however, has been limited so far to the treatment of classic Hodgkin’s lymphoma, which portrays a typical overexpression of PD-1 ligands (PD-L1, PD-L2) as a consequence of changes in chromosome 9p24.1. Their current application in multiple myeloma (MM) is rather uncertain, as discordant results have been reported by distinct research groups concerning especially the expression of PD-1/PD-L1 molecules on malignant plasma cells or on the responsible immune effector cell populations, respectively. In MM it seems that an approach based on combination treatment might be appropriate as unsatisfactory results have been yielded by monotherapy with PD-1/PD-L1 inhibitors. Immunomodulatory drugs, which are the current cornerstone of MM treatment, are the most logical partners as they possess many possibly synergistic effects. Nevertheless, the initially optimistic results have become disappointing due to the excessive and unpredictable toxicity of the combination of pembrolizumab with lenalidomide or pomalidomide. The FDA has suspended or put on hold several phase 3 trials in relapsed as well as in newly diagnosed myeloma patients. There are also other potentially synergistic and promising combinations, such as the anti-CD38 monoclonal antibody daratumumab, irradiation, etc. Not only the effective partner but also the correct timing of the initiation of the PD-1/PD-L1 inhibitors treatment seems to be of utmost importance. These strategies are currently being examined in various stages of myeloma such as during consolidation post autologous stem cell transplantation, targeting minimal residual disease or even in high risk smoldering myeloma. | es_ES |
dc.description.sponsorship | The authors want to give special thanks to Jana Mihalyova, MD and Denisa Hrncirova for their help with the preparation of the manuscript and to Shira Timilsina Godfrey, MD for editing the article. This work was supported by MH CZ—DRO (FNOs/2018), by the Institutional Development Plan of University of Ostrava, financial resources are allocated by The Ministry of Education, Youth and Sports (project no. IRP03_2018-2020) and also by financial support from the project Cell Coolab Ostrava–Research and Development Center for Cell Therapy in Hematology and Oncology (No.C.Z.02.1.01/0.0/0.0/17_049/ 0008440) financially supported from ERDF. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.subject | PD-1 | es_ES |
dc.subject | PD-L1 | es_ES |
dc.subject | Pembrolizumab | es_ES |
dc.subject | Nivolumab | es_ES |
dc.subject | Durvalumab | es_ES |
dc.subject | Safety | es_ES |
dc.subject | Toxicity | es_ES |
dc.title | Update on PD-1/PD-L1 inhibitors in multiple myeloma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | es_ES |
dc.identifier.doi | 10.3389/fimmu.2018.02431 | - |
dadun.citation.publicationName | Frontiers in immunology | es_ES |
dadun.citation.startingPage | 2431 | es_ES |
dadun.citation.volume | 9 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.